Supplementary Table 1. PIK3CA mutation in colorectal cancer
|
|
- Victor Charles
- 5 years ago
- Views:
Transcription
1 Liao X et al. PIK3CA Mutation in Colorectal Cancer. Page 1 Supplementary Table 1. PIK3CA mutation in colorectal cancer Exon Domain Nucleotide change* Amino acid change* cases 9 Helical c.1621t>a p.e541t 1 9 Helical c.1624g>a p.e542k 40 # 9 Helical c.1631c>a p.t544n 3 # 9 Helical c.1631c>t p.t544i 1 9 Helical c.1633g>a p.e545k 57 9 Helical c.1634a>c p.e545a 1 9 Helical c.1634a>g p.e545g 1 9 Helical c.1636c>a p.q546k 14 # 20 Kinase c.3129g>t p.m1043i Kinase c.3133g>a p.d1045n 1 20 Kinase c.3136g>a p.a1046t 2 20 Kinase c.3137c>a p.a1046e 1 20 Kinase c.3139c>t p.h1047y 5 20 Kinase c.3140a>c p.h1047p 1 20 Kinase c.3140a>g p.h1047r Kinase c.3140a>t p.h1047l 11 # 20 Kinase c.3142c>t p.h1048y 1 # *Nomenclature of mutation follows the recommendations by the Human Genome Variation Society ( # One case had both c.1636c>a and c.1631c>a mutations, another had c.3140a>t and c.3142c>t mutations and another had c.1624g>a and c.1631c>a mutations.
2 Liao X et al. PIK3CA Mutation in Colorectal Cancer. Page 2 Supplementary Table 2. Clinical, pathological and molecular features of colorectal cancer according to PIK3CA mutation status in the Nurses Health Study PIK3CA wildtype Only in exon 9 PIK3CA mutation present P (exon 9 Only in exon vs. 20 exon 20) Feature No. No. No. No. No. No In both exon 9 and exon 20 P (across all categories) Mean age at diagnosis (years) ± SD 66.7 ± ± ± ± ± Year of diagnosis Prior to % % 19 36% 12 32% 1 50% 1997 or after % % 34 64% 25 68% 1 50% Family history of colorectal cancer in first degree relatives Absent % % 44 83% 28 76% 1 50% Present % % 9 17% 9 24% 1 50% Tumor location Rectum % % 10 19% 5 14% 0 0 Distal colon % % 15 28% 13 35% 1 50% Proximal colon % % 28 53% 19 51% 1 50% Disease stage I % % 17 32% 6 16% 0 0 II % % 16 30% 14 38% 1 50% III % % 13 25% 11 30% 1 50% IV 85 13% 72 13% 7 13% 6 16% 0 0 Unknown 31 5% 31 6% % 0 0
3 Liao X et al. PIK3CA Mutation in Colorectal Cancer. Page 3 Tumor grade Low % % 50 94% 31 84% 2 100% High 73 12% 64 12% 3 6% 6 16% 0 0 MSI status MSI-low/MSS % % 46 87% 28 76% 2 100% MSI-high % % 7 13% 9 24% 0 0 CIMP status CIMP-low/ % % 45 88% 27 73% 1 50% CIMP-high % % 6 12% 10 27% 1 50% BRAF status Wild-type % % 47 89% 27 75% 2 100% Mutant % % 6 11% 9 25% 0 0 KRAS status Wild-type % % 25 47% % 1 50% Mutant % % 28 53% 15 42% 1 50% Mean LINE-1 methylation level (%) ± SD 63.1 ± ± ± ± ± TP53 expression Negative % % 32 74% 21 70% 1 50% Positive % % 11 26% 9 30% 1 50%
4 Liao X et al. PIK3CA Mutation in Colorectal Cancer. Page 4 Supplementary Table 3. Clinical, pathological and molecular features of colorectal cancer according to PIK3CA mutation status in the Health Professionals Follow-Up Study PIK3CA mutation present PIK3CA wildtype exon 9 (exon 9 vs. exon 20 9 and exon 20 Only in P Only in In both exon Feature No. No. No. exon 20) No. No. No P (across all categories) Mean age at diagnosis (years) ± SD 71.1 ± ± ± ± ± Year of diagnosis Prior to % % 24 43% 19 53% 2 40% 1997 or after % % 32 57% 17 47% 3 60% Family history of colorectal cancer in first degree relatives Absent % % 46 82% 26 72% 2 40% Present 99 18% 76 17% 10 18% 10 28% 3 60% Tumor location Rectum % % 7 13% 5 14% 1 20% Distal colon % % 17 30% 12 33% 1 20% Proximal colon % % 32 57% 19 53% 3 60% Disease stage I % % 16 29% 9 25% 3 60% II % % 12 21% 14 39% 0 0 III % % 11 20% 8 22% 0 0 IV 66 12% 52 12% 8 14% 4 11% 2 40% Unknown 71 13% 61 14% 9 16% 1 3% 0 0
5 Liao X et al. PIK3CA Mutation in Colorectal Cancer. Page 5 Tumor grade Low % % 52 95% 32 89% 5 100% High 38 7% 31 7% 3 5% 4 11% 0 0 MSI status MSI-low/MSS % % 54 96% 24 69% 4 80% MSI-high 60 11% 46 11% 2 4% 11 31% 1 20% CIMP status CIMP-low/ % % 43 86% 25 74% 3 60% CIMP-high 58 12% 40 10% 7 14% 9 26% 2 40% BRAF status Wild-type % % 52 93% 30 83% 4 80% Mutant 43 8% 32 7% 4 7% 6 17% 1 20% KRAS status Wild-type % % 23 41% 17 47% 1 20% Mutant % % 33 59% 19 58% 4 80% Mean LINE-1 methylation level (%) ± SD 62.4 ± ± ± ± ± TP53 expression Negative % % 24 69% 18 67% 2 67% Positive % % 11 31% 9 33% 1 33%
6 Liao X et al. PIK3CA Mutation in Colorectal Cancer. Page 6 Supplementary Table 4. Clinical, pathological and molecular features of colorectal cancer according to overall PIK3CA mutation status PIK3CA wildtype mutant PIK3CA P Feature No. No. No. No Sex Male % % 97 51% Female % % 92 49% Mean age (years) ± SD 68.7 ± ± ± Year of diagnosis 0.53 Prior to % % 77 41% 1997 or after % % % Family history of colorectal cancer in first degree relatives 0.18 Absent % % % Present % % 42 22% Tumor location Rectum % % 28 15% Distal colon % % 59 31% Proximal colon % % % Disease stage 0.25 I % % 51 27% II % % 57 30% III % % 44 23% IV % % 27 14% Unknown 102 9% 92 9% 10 6% Tumor grade 0.60 Low % % % High 111 9% 95 10% 16 9% MSI status 0.77 MSI-low/MSS % % % MSI-high % % 30 16%
7 Liao X et al. PIK3CA Mutation in Colorectal Cancer. Page 7 CIMP status 0.34 CIMP-low/ % % % CIMP-high % % 35 20% BRAF status 0.72 Wild-type % % % Mutant % % 26 14% KRAS status < Wild-type % % 88 47% Mutant % % % Mean LINE-1 methylation level (%) ± SD 62.8 ± ± ± TP53 expression Negative % % 98 70% Positive % % 42 30%
8 Liao X et al. PIK3CA Mutation in Colorectal Cancer. Page 8 Supplementary Table 5. analysis of the relations between KRAS mutation and PIK3CA mutation in colorectal cancers Variable independently associated with PIK3CA OR P KRAS mutation vs wild-type 2.65 ( ) < Other variables in the model CIMP high vs low/ ( ) The multivariate logistic regression model initially included age, sex, year of diagnosis, tumor location, microsatellite instability, CpG island methylator phenotype, KRAS, BRAF and LINE-1 methylation. A backward elimination with threshold of p=0.05 was used to select variables in the final models. CI, confidence interval; OR, odds ratio.
9 Liao X et al. PIK3CA Mutation in Colorectal Cancer. Page 9 Supplementary Table 6. PIK3CA exon 9 or exon 20 mutation in colorectal cancer and patient mortality PIK3CA status No. Colorectal cancer-specific mortality Overall mortality Stagestratified (95% Stagestratified (95% Wild-type (referent) 1 (referent) 1 (referent) (referent) 1 (referent) 1 (referent) Exon 9 mutant (regardless of exon 20 status) Exon 20 mutant (regardless of exon 9 status) ( ) 0.96 ( ) 1.15 ( ) 1.01 ( ) 1.15 ( ) 1.11 ( ) ( ) 0.90 ( ) 1.09 ( ) 0.94 ( ) 0.98 ( ) 0.92 ( ) The multivariate, stage-stratified Cox regression model initially included age, sex, year of diagnosis, tumor location, tumor grade, microsatellite instability, CpG island methylator phenotype, KRAS mutation, BRAF mutation, LINE-1 methylation and PIK3CA mutation status in the other exon. A backward elimination with a threshold of P = 0.05 was used to select variables in the final models. CI, confidence interval;, hazard ratio.
10 Liao X et al. PIK3CA Mutation in Colorectal Cancer. Page 10 Supplementary Table 7. PIK3CA mutation in colorectal cancer and patient mortality according to cohort (gender) Colorectal cancer-specific mortality Overall mortality PIK3CA status No. Stagestratified (95% Stagestratified (95% Men (HPFS) Women (NHS) Wild-type (referent) 1 (referent) 1 (referent) (referent) 1 (referent) 1 (referent) Mutant ( ) 1.07 ( ) 1.01 ( ) ( ) 1.03 ( ) 0.93 ( ) Wild-type (referent) 1 (referent) 1 (referent) (referent) 1 (referent) 1 (referent) Mutant ( ) 1.00 ( ) 1.11 ( ) ( ) 0.85 ( ) 0.88 ( ) The multivariate, stage-stratified Cox regression model initially included age, sex, year of diagnosis, tumor location, tumor grade, microsatellite instability, CpG island methylator phenotype, KRAS mutation, BRAF mutation and LINE-1 methylation. A backward elimination with a threshold of P = 0.05 was used to select variables in the final models. CI, confidence interval; HPFS, Health Professionals Follow-Up Study;, hazard ratio; NHS, Nurses Health Study.
11 Liao X et al. PIK3CA Mutation in Colorectal Cancer. Page 11 Supplementary Table 8. Combined PIK3CA and BRAF mutation status in colorectal cancer and patient mortality PIK3CA BRAF No. Colorectal cancer-specific mortality Overall mortality Stagestratified stratified Stage- (95% (95% Wild-type Wild-type (referent) 1 (referent) 1 (referent) (referent) 1 (referent) 1 (referent) Mutant Wild-type Wild-type Mutant Mutant Mutant ( ) 1.09 ( ) 1.24 ( ) 0.82 ( ) 1.11 ( ) 1.19 ( ) 0.80 ( ) 1.37 ( ) 2.40 ( ) ( ) 1.17 ( ) 1.06 ( ) 0.88 ( ) 1.21 ( ) 1.07 ( ) 0.80 ( ) 1.34 ( ) 1.48 ( ) PIK3CA KRAS Wild-type Wild-type (referent) 1 (referent) 1 (referent) (referent) 1 (referent) 1 (referent) Mutant Wild-type Wild-type Mutant Mutant Mutant ( ) 1.42 ( ) 1.18 ( ) 0.97 ( ) 1.19 ( ) 0.87 ( ) 1.0 ( ) 1.17 ( ) 0.85 ( ) ( ) 1.27 ( ) 1.11 ( ) 0.91 ( ) 1.15 ( ) 0.93 ( ) 0.89 ( ) 1.09 ( ) 0.84 ( ) The multivariate, stage-stratified Cox regression model initially included age, sex, year of diagnosis, tumor location, tumor grade, microsatellite instability, CpG island methylator phenotype, KRAS mutation and LINE-1 methylation. A backward elimination with a threshold of P = 0.05 was used to select variables in the final models. CI, confidence interval;, hazard ratio.
Whole Exome Sequenced Characteristics
Supplementary Tables Supplementary Table 1: Patient characteristics of 45 whole exome sequenced HNSCC tumors Whole Exome Sequenced Characteristics Tumors (n=45) Age, years Median (range) 61.0 (19-90) Sex,
More informationJuly 2015 Assay ID Assay Name Gene COSMIC ID Amino acid change Nucleotide change Wild type allele (VIC label) Mutant allele (FAM label)
July 2015 Assay ID Assay Name Gene COSMIC ID Amino acid change Nucleotide change Wild type allele (VIC label) Mutant allele (FAM label) p AHLJ090 AKT1_33765 AKT1 33765 p.e17k c.49g>a C T 2 AHBKFRM BRAF_473
More informationSerrated Polyps and a Classification of Colorectal Cancer
Serrated Polyps and a Classification of Colorectal Cancer Ian Chandler June 2011 Structure Serrated polyps and cancer Molecular biology The Jass classification The familiar but oversimplified Vogelsteingram
More informationSupplementary Table 2. Identified causative mutations and/or mutation candidates.
Supplementary Table 2. Identified causative mutations and/or mutation candidates. Nonsense mutations base change aa change Average depth Result of next generation in 432 patient Hereditary form of the
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationSupplementary Figure 1
Supplementary Figure 1 A B HEC1A PTEN +/+ HEC1A PTEN -/- 16 HEC1A PTEN -/- 22 PTEN RAD51 % Cells with RAD51 foci 40 -IR +IR 30 20 10 * *! TUBULIN 0 HEC1A PTEN+/+ HEC1A PTEN-/- 16 HEC1A PTEN-/- 22 C D 1.0
More informationAspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival Xiaoyun Liao, M.D., Ph.D., Paul Lochhead, M.B., Ch.B., Reiko Nishihara,
More informationIan Landry, MPH Beth Schmidt, MSPH
Mary Charlton, PhD Bobbi Matt, CTR Mary Anne Lynch, MPH Vivien Chen, PhD Ian Landry, MPH Beth Schmidt, MSPH Response to EGFR inhibitors is poorer among Stage IV colorectal cancer (CRC) patients with KRAS
More informationCollaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation
Collaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation Dr Jenni Fairley Deputy Scheme Director (Molecular Pathology), GenQA, Edinburgh, UK From 1 st
More informationBeyond the APC era Alternative pathways to CRC. Jeremy R Jass McGill University
Beyond the APC era Alternative pathways to CRC Jeremy R Jass McGill University Outline Limitations of APC model KRAS and serrated polyps CRC and CpG island methylation Serrated pathway to CRC Fusion pathways
More informationThe Personalized Cancer Medicine Initiative at Vanderbilt
The Personalized Cancer Medicine Initiative at Vanderbilt October 26, 2009 William Pao, MD, PhD Assistant Director, Personalized Cancer Medicine Vanderbilt-Ingram Cancer Center Cancer in the United States,
More informationPersonalized Aspirin Therapy
Personalized Aspirin Therapy Nadir Arber, MD, MSc, MHA Head - Integrated Cancer Prevention Center Tel Aviv Medical Centre and Tel Aviv University Heidelberg 2014 CRC is Preventable Early detection Chemoprevention
More informationThe Role of the CpG Island Methylator Phenotype on Survival Outcome in Colon Cancer
Gut and Liver, Vol. 9, No. 2, March 215, pp. 22-27 ORiginal Article The Role of the CpG Island Methylator Phenotype on Survival Outcome in Colon Cancer Ki Joo Kang*, Byung-Hoon Min, Kyung Ju Ryu, Kyoung-Mee
More informationIntegration of Cancer Genome into GECCO- Genetics and Epidemiology of Colorectal Cancer Consortium
Integration of Cancer Genome into GECCO- Genetics and Epidemiology of Colorectal Cancer Consortium Ulrike Peters Fred Hutchinson Cancer Research Center University of Washington U01-CA137088-05, PI: Peters
More informationGeneral Session 7: Controversies in Screening and Surveillance in Colorectal Cancer
General Session 7: Controversies in Screening and Surveillance in Colorectal Cancer Complexities of Pathological Assessment: Serrated Polyps/Adenomas Carolyn Compton, MD, PhD Professor of Life Sciences,
More informationClinical and Pathological Significance of Epigenomic Changes in Colorectal Cancer
Clinical and Pathological Significance of Epigenomic Changes in Colorectal Cancer Shuji Ogino, M.D., Ph.D. Associate Professor of Pathology Harvard Medical School Brigham and Women s Hospital Dana-Farber
More informationMolecular biology of colorectal cancer
Molecular biology of colorectal cancer Phil Quirke Yorkshire Cancer Research Centenary Professor of Pathology University of Leeds, UK Rapid pace of molecular change Sequencing changes 2012 1,000 genomes
More informationThe molecular genetics of colorectal cancer
1 Department of Gastroenterology, North Middlesex University Hospital, London, UK 2 Institute of Molecular Genetics, Cardiff University 3 Department of Gastroenterology, Queen s Hospital Romford, London,
More informationINTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 38: Received November 13, 2015; Accepted March 11, DOI: /ijmm.2016.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 38: 687-702 2016 Serrated polyposis associated with a family history of colorectal cancer and/or polyps: The preferential location of polyps in the colon and
More informationThis is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/95828/ This is the author s version of a work that was submitted to / accepted
More informationThe Role of Next Generation Sequencing in Solid Tumor Mutation Testing
The Role of Next Generation Sequencing in Solid Tumor Mutation Testing Allie H. Grossmann MD PhD Department of Pathology, University of Utah Division of Anatomic Pathology & Oncology, ARUP Laboratories
More informationSupplementary Online Content
Supplementary Online Content Venook AP, Niedzwiecki D, Lenz H-J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced
More informationSUPPLEMENTARY FIGURES: Supplementary Figure 1
SUPPLEMENTARY FIGURES: Supplementary Figure 1 Supplementary Figure 1. Glioblastoma 5hmC quantified by paired BS and oxbs treated DNA hybridized to Infinium DNA methylation arrays. Workflow depicts analytic
More informationMarcatori biomolecolari dei carcinomi del colon-retto sporadici ed ereditari
Marcatori biomolecolari dei carcinomi del colon-retto sporadici ed ereditari Milo Frattini XII Congresso AIFEG Villa Cagnola - Gazzada Schianno (VA) 16/17.10.2014 APC β-catenina APC Met (p16) Models of
More informationRecent advances in the molecular pathology of lung cancer: role of EGFR and KRAS mutation testing in treatment selection
ASIP 2009 USCAP Companion Meeting Molecular Pathology for the Practicing Pathologist Recent advances in the molecular pathology of lung cancer: role of EGFR and KRAS mutation testing in treatment selection
More informationNetherlands Cohort Study on diet and cancer NLCS
Netherlands Cohort Study on diet and cancer NLCS Leo Schouten Matty Weijenberg Maastricht University GROW-School for Oncology and Developmental Biology Department of Epidemiology Design PI s: Piet van
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More informationLa genetica del carcinoma colo-rettale
La genetica del carcinoma colo-rettale Ivana Cataldo Ospedale Ca Foncello, Treviso ARC-NET Centro di Ricerca Applicata sul Cancro AOUI, Verona OUTLINE What s new in colorectal cancer? Pathological Markers
More informationGender-related prognostic value and genomic pattern of intra-tumor heterogeneity in colorectal cancer
Carcinogenesis, 2017, Vol. 38, No. 8, 837 846 doi:10.1093/carcin/bgx046 Advance Access publication May 20, 2017 Original Manuscript original manuscript Gender-related prognostic value and genomic pattern
More informationColon Cancer and Hereditary Cancer Syndromes
Colon Cancer and Hereditary Cancer Syndromes Gisela Keller Institute of Pathology Technische Universität München gisela.keller@lrz.tum.de Colon Cancer and Hereditary Cancer Syndromes epidemiology models
More informationBRAF Testing In The Elderly: Same As in Younger Patients?
EGFR, K-RAS, K BRAF Testing In The Elderly: Same As in Younger Patients? Nadine Jackson McCleary MD MPH Gastrointestinal Oncology Dana-Farber/Harvard Cancer Care Boston, MA, USA Outline Colorectal cancer
More informationMUTATION TEST CE IVD. ctnras-braf FEATURES
ctnras-braf CE IVD TECHNICAL SHEET IDYLLA ctnras-braf MUTATION TEST The Idylla ctnras-braf Mutation Test, performed on the Biocartis Idylla System, is an in vitro diagnostic test for the qualitative detection
More informationPersonalized Gene Profile
Sequence Variants: 6 4 ALTERATION MUTANT FRACTION FDA GUIDANCE (for indication) FDA GUIDANCE (for other indications) TRIALS (details below) c.38g>a; p.g13d 21.0% Cetuximab Contraindicated 22 Panitumumab
More informationSessile Serrated Polyps
Årsmøtet i Den norske Patologforening 2014 Sessile Serrated Polyps Tor J. Eide Oslo Universitetssykehus The term serrated include a group of lesions with a sawtoothlike appearance of the crypts and the
More informationNames for H (ISBT 018) Blood Group Alleles
Names for H (ISBT 018) Blood Group Alleles General description: The H blood group system consists of one antigen, H, that is carried on glycolipids and glycoproteins on the RBC membrane, where it is synthesised
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More information(a) Schematic diagram of the FS mutation of UVRAG in exon 8 containing the highly instable
Supplementary Figure 1. Frameshift (FS) mutation in UVRAG. (a) Schematic diagram of the FS mutation of UVRAG in exon 8 containing the highly instable A 10 DNA repeat, generating a premature stop codon
More informationTitle:BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients
Author's response to reviews Title:BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients Authors: Jing Chen (jingchen871227@126.com) Fang Guo (wukongxiaofang@126.com)
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationMicrosatellite instability and other molecular markers: how useful are they?
Microsatellite instability and other molecular markers: how useful are they? Pr Frédéric Bibeau, MD, PhD Head, Pathology department CHU de Caen, Normandy University, France ESMO preceptorship, Barcelona,
More informationColorectal Cancer - Working in Partnership. David Baty Genetics, Ninewells Hospital
Colorectal Cancer - Working in Partnership David Baty Genetics, Ninewells Hospital Genetics and Pathology National initiatives Colorectal cancer Inherited CRC Sporadic CRC The Liquid Biopsy The future?
More informationDescription of Supplementary Files. File Name: Supplementary Information Description: Supplementary Figures and Supplementary Tables
Description of Supplementary Files File Name: Supplementary Information Description: Supplementary Figures and Supplementary Tables Supplementary Figure 1: (A), HCT116 IDH1-WT and IDH1-R132H cells were
More informationSupplementary Table 1. Association of rs with risk of obesity among participants in NHS and HPFS
Supplementary Table 1. Association of rs3826795 with risk of obesity among participants in NHS and HPFS Case/control NHS (1990) HPFS (1996) OR (95% CI) P- value Case/control OR (95% CI) P- value Obesity
More informationThe left versus right colon cancer story What is the truth?
The left versus right colon cancer story What is the truth? Prof. V. Heinemann CCC LMU, Klinikum Grosshadern Ludwig-Maximilian-University of Munich, Germany Three stages of truth (Schopenhauer) Ridicule
More informationColorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More informationBiomarker development in the era of precision medicine. Bei Li, Interdisciplinary Technical Journal Club
Biomarker development in the era of precision medicine Bei Li, 23.08.2016 Interdisciplinary Technical Journal Club The top ten highest-grossing drugs in the United States help between 1 in 25 and 1 in
More information6/12/2018. Disclosures. Clinical Genomics The CLIA Lab Perspective. Outline. COH HopeSeq Heme Panels
Clinical Genomics The CLIA Lab Perspective Disclosures Raju K. Pillai, M.D. Hematopathologist / Molecular Pathologist Director, Pathology Bioinformatics City of Hope National Medical Center, Duarte, CA
More informationADVANCES IN COLON CANCER
ADVANCES IN COLON CANCER Peter T. Silberstein, M.D., FACP Professor, Creighton University Chief Hematology/Oncology UNIVERSAL SCREENING FOR LYNCH SYNDROME OF ALL PATIENTS WITH COLON CANCER ADOPTED BY CHI
More informationAnatomic Molecular Pathology: An Emerging Field
Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania asepu@mail.med.upenn.edu 2008 ASIP Annual Meeting Anatomic pathology (U.S.) is a medical specialty
More informationColon cancer: practical molecular diagnostics. Wade S. Samowitz, M.D. University of Utah and ARUP
Colon cancer: practical molecular diagnostics Wade S. Samowitz, M.D. University of Utah and ARUP Disclosure Dr. Samowitz may receive royalties in the future related to the Ventana BRAF V600E antibody.
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Sherman SI, Wirth LJ, Droz J-P, et al. Motesanib diphosphate
More informationColorectal Cancer Expression of Peroxisome Proliferator-Activated Receptor (PPARG, PPARgamma) Is Associated With Good Prognosis
GASTROENTEROLOGY 2009;136:1242 1250 Colorectal Cancer Expression of Peroxisome Proliferator-Activated Receptor (PPARG, PPARgamma) Is Associated With Good Prognosis SHUJI OGINO,*,, KAORI SHIMA,* YOSHIFUMI
More informationSupplementary Document
Supplementary Document 1. Supplementary Table legends 2. Supplementary Figure legends 3. Supplementary Tables 4. Supplementary Figures 5. Supplementary References 1. Supplementary Table legends Suppl.
More informationTargeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes KM Kortüm 1,8 *, EK Mai 3,4 *, NH Hanafiah 3 *, CX Shi 1, YX Zhu 1, L Bruins 1, S Barrio 1,
More informationMolecular subtyping: how useful is it?
Molecular subtyping: how useful is it? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics at the NCT-Partner Site Dresden CMTD Disclosure
More informationColorectal cancer Chapelle, J Clin Oncol, 2010
Colorectal cancer Chapelle, J Clin Oncol, 2010 Early-Stage Colorectal cancer: Microsatellite instability, multigene assay & emerging molecular strategy Asit Paul, MD, PhD 11/24/15 Mr. X: A 50 yo asymptomatic
More informationSupplementary Table 3. 3 UTR primer sequences. Primer sequences used to amplify and clone the 3 UTR of each indicated gene are listed.
Supplemental Figure 1. DLKI-DIO3 mirna/mrna complementarity. Complementarity between the indicated DLK1-DIO3 cluster mirnas and the UTR of SOX2, SOX9, HIF1A, ZEB1, ZEB2, STAT3 and CDH1with mirsvr and PhastCons
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationSuspected Renal Colic in the Emergency Department
Suspected Renal Colic in the Emergency Department Who Needs Urologic Intervention? Yan JW, McLeod SL, Edmonds ML, Sedran RJ, Theakston KD CAEP June 4, 2012 Disclosure No conflicts of interest to declare
More informationNature Genetics: doi: /ng Supplementary Figure 1. Alternative splicing events in the 5K panel.
Supplementary Figure 1 Alternative splicing events in the 5K panel. The majority of cryptic splicing occurred by creation of an AG or GT (Type I). While some other mutations increased the usage of a nearby
More informationVariant interpretation exercise. ACGS Somatic Variant Interpretation Workshop Joanne Mason 21/09/18
Variant interpretation exercise ACGS Somatic Variant Interpretation Workshop Joanne Mason 21/09/18 Format of exercise Compile a list of tricky variants across solid cancer and haematological malignancy.
More informationSupplementary Online Content
Supplementary Online Content Pearlman R, Frankel WL, Swanson B, et al. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol.
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal surgery prior as factor in laparoscopic colorectal surgery, 554 555 Abscess(es) CRC presenting as, 539 540 Adenocarcinoma of
More informationT ranscriptional inactivation by cytosine methylation at
1000 GASTROINTESTINAL CANCER CpG island methylator phenotype () of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies S Ogino, M Cantor, T Kawasaki,
More informationOverView Circulating Nucleic Acids (CFNA) in Cancer Patients. Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA
OverView Circulating Nucleic Acids (CFNA) in Cancer Patients Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA cfna Blood Assays Cell-free nucleic acids as biomarkers in cancer patients.
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationGenetic testing all you need to know
Genetic testing all you need to know Sue Clark Consultant Colorectal Surgeon, St Mark s Hospital, London, UK. Colorectal cancer Familial 33% Polyposis syndromes
More informationKRAS, NRAS, and BRAF Variant Analysis in Metastatic Colorectal Cancer
KRAS, NRAS, and BRAF Variant Analysis in Metastatic Colorectal Cancer Policy Number: 2.04.53 Last Review: 5/2018 Origination: 1/2011 Next Review: 5/2019 Policy Blue Cross and Blue Shield of Kansas City
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
KRAS, NRAS, and BRAF Variant Analysis in Metastatic Colorectal Cancer Page 1 of 25 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: KRAS, NRAS, and BRAF Variant Analysis
More informationSerrated Colorectal Polyps and the Serrated Neoplasia Pathway
Serrated Colorectal Polyps and the Serrated Neoplasia Pathway An update on the pathology and clinical significance Mark Be(ngton Envoi Specialist Pathologists Overview 1. A framework of what is included
More informationReport OPERRA Workshop: Modelling of pathogenesis
Report OPERRA Workshop: Modelling of pathogenesis Markus Eidemüller a, Christian Kaiser a, E. Georg Luebeck b, William Paul Accomando c, Kristian Unger a, Mark van de Wiel d, Jonas Behr e, Marc Chadeau-Hyam
More informationSupplementary Figure 1 MicroRNA expression in human synovial fibroblasts from different locations. MicroRNA, which were identified by RNAseq as most
Supplementary Figure 1 MicroRNA expression in human synovial fibroblasts from different locations. MicroRNA, which were identified by RNAseq as most differentially expressed between human synovial fibroblasts
More informationNature Medicine: doi: /nm.3967
Supplementary Figure 1. Network clustering. (a) Clustering performance as a function of inflation factor. The grey curve shows the median weighted Silhouette widths for varying inflation factors (f [1.6,
More informationNivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142
Nivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142 Abstract #519 Overman MJ, Lonardi S, Leone F, McDermott
More informationSample Report. Result: POSITIVE Mutations Detected: NRAS-G13V, TP53-R282W, TP53-G245D, TP53-R175H, BRAF-V600M, MSI-High
Sample Report PATIENT INFORMATION Name: DOB: Age: Sex: Address: Doe, John 09/04/1969 49 Male South Plainfield, NJ, 07080 SAMPLE INFORMATION Date Collected: Date Received: Date of Report: lab ID: Testing
More informationORIGINAL ARTICLE. and treatment of patients
ONLINE FIRST ORIGINAL ARTICLE Predictors of Lymph Node Count in Colorectal Cancer Resections Data From US Nationwide Prospective Cohort Studies Teppei Morikawa, MD, PhD; Noriko Tanaka, PhD; Aya Kuchiba,
More informationOut-Patient Billing CPT Codes
Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB
More informationGenetic Alteration Panels
TM Genetic Alteration Panels GENETIC ALTERATION PANELS Table of Contents AKT Genetic Alteration Panel (ATCC No. TCP-1029 )...1 BRAF Genetic Alteration Panel (ATCC No. TCP-1032 )...5 EGFR Genetic Alteration
More informationPublished OnlineFirst October 14, 2009; DOI: / CCR
Published OnlineFirst October 14, 2009; DOI: 10.1158/1078-0432.CCR-09-1438 Imaging, Diagnosis, Prognosis Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph
More informationResectable locally advanced oesophagogastric cancer
Resectable locally advanced oesophagogastric cancer Clinical Case Discussion Florian Lordick University Cancer Center Leipzig University Clinic Leipzig Leipzig, Germany esmo.org DISCLOSURES Honoraria for
More informationMolecular Diagnosis for Colorectal Cancer Patients
Molecular Diagnosis for Colorectal Cancer Patients Antonia R. Sepulveda MD, PhD, FCAP October, 20, 2010 www.cap.org Welcome to the PHC Webinar Series This talk on The Molecular Diagnosis for Colorectal
More informationRelated Policies None
Medical Policy MP 2.04.53 BCBSA Ref. Policy: 2.04.53 Last Review: 07/25/2018 Effective Date: 07/25/2018 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
More informationNames for ABO (ISBT 001) Blood Group Alleles
Names for ABO (ISBT 001) blood group alleles v1.1 1102 Names for ABO (ISBT 001) Blood Group Alleles General description: The ABO system was discovered as in 1900 and is considered the first and clinically
More informationRESEARCH ARTICLE. Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis
RESEARCH ARTICLE Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis Yusuke Sasaki 1,2, Tetsuya Hamaguchi 1 *, Yasuhide Yamada
More informationToxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -
Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationIntron p Hybrid with p.leu245val p. Gly336Cys. p.leu62phe p. Ala137Val p. Asn152Thr hybrid with p.leu245val p.
RHD negative, i.e. null Phenotype Allele name Nucleotide change Exon Predicted amino acid change D RHD*01N.01 RHD deletion 1-10 p.0 Allele name detail Comments D RHD*08N.01 RHD*Pseudogene RHD* Ψ 37- bp
More informationCaring for a Patient with Colorectal Cancer. Objectives. Poll question. UNC Cancer Network Presented on 10/15/18. For Educational Use Only 1
Caring for a Patient with Colorectal Cancer Tammy Triglianos RN, APRN-BC, AOCNP Nurse Practitioner, GI Oncology 10/15/2018 Objectives Describe common signs and symptoms of colorectal cancer Understand
More informationVectibix. Vectibix (panitumumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.85 Subject: Vectibix Page: 1 of 5 Last Review Date: December 2, 2016 Vectibix Description Vectibix
More informationSynchronous and Subsequent Lesions of Serrated Adenomas and Tubular Adenomas of the Colorectum
Tsumura T, et al 1 Synchronous and Subsequent Lesions of Serrated Adenomas and Tubular Adenomas of the Colorectum T. Tsumura a T. Hiyama d S. Tanaka b M. Yoshihara d K. Arihiro c K. Chayama a Departments
More informationBMJ Open. A Nationwide Danish Cohort Study challenging the Categorization into Right Sided and Left Sided Colon Cancer
A Nationwide Danish Cohort Study challenging the Categorization into Right Sided and Left Sided Colon Cancer Journal: BMJ Open Manuscript ID: bmjopen-0-000 Article Type: Research Date Submitted by the
More informationPrognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Bruno Vincenzi Università Campus Bio-Medico di Roma
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients Bruno Vincenzi Università Campus Bio-Medico di Roma Colorectal cancer 3 rd most common cancer worldwide Approximately
More informationColorectal Cancer Structured Pathology Reporting Proforma DD MM YYYY
Colorectal Cancer Structured Pathology Reporting Proforma Mandatory questions (i.e. protocol standards) are in bold (e.g. S1.03). Family name Given name(s) Date of birth DD MM YYYY S1.02 Clinical details
More informationKolorektalni karcinom- novosti u liječenju. PANEL: Maja Banjin, Janja Ocvirk, Borislav Belev, Ivan Nikolić, Anes Pašić
Kolorektalni karcinom- novosti u liječenju PANEL: Maja Banjin, Janja Ocvirk, Borislav Belev, Ivan Nikolić, Anes Pašić Kolorektalni karcinomnovosti u liječenju PANEL : Maja Banjin, Janja Ocvirk, Borislav
More informationNIH Public Access Author Manuscript Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2010 December 1.
NIH Public Access Author Manuscript Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2009 December ; 18(12): 3384 3388. doi: 10.1158/1055-9965.EPI-09-0955. Assessing tumor mutations
More informationLOINC. Clinical information. RCPA code. Record if different to report header Operating surgeon name and contact details. Absent.
Complete as narrative or use the structured format below 55752-0 17.02.28593 Clinical information 22027-7 17.02.30001 Record if different to report header Operating surgeon name and contact details 52101004
More informationLeveraging Prospective Cohort Studies to Advance Colorectal Cancer Prevention, Treatment and Biology
Leveraging Prospective Cohort Studies to Advance Colorectal Cancer Prevention, Treatment and Biology Charles S. Fuchs, MD, MPH Director, Yale Cancer Center Physician-in-Chief, Smilow Cancer Hospital New
More informationAnalysis of factors influencing molecular testing at diagnostic of colorectal cancer
Thiebault et al. BMC Cancer (2017) 17:765 DOI 10.1186/s12885-017-3759-6 RESEARCH ARTICLE Analysis of factors influencing molecular testing at diagnostic of colorectal cancer Quentin Thiebault 1, Gautier
More informationw ª wy xvwz A ª vw xvw P ª w} xvw w Æ w Æ V w,x Æ w Æ w Æ y,z Æ { Æ y,z, w w w~ w wy}æ zy Æ wyw{ xæ wz w xywæ xx Æ wv Æ } w x w x w Æ w Æ wy} zy Æ wz
w ª wy xvwz A ª vw xvw P ª w} xvw w Æ w Æ V w,x Æ w Æ w Æ y,z Æ { Æ y,z, w w w~ w wy}æ zy Æ wyw{ xæ wz w xywæ xx Æ wv Æ } w x w x w Æ w Æ wy} zy Æ wz {w Æ Æ wyw{ x w Germ-line mutations in BRCA1 are associated
More informationB Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696
Index Note: Page numbers of article titles are in boldface type. A Adenomatous polyposis, familial. See Familial adenomatous polyposis. Anal anastomosis, ileal-pouch, proctocolectomy with, in FAP, 591
More information